## Page 1 of 2 10/585,017 Form PTO-1449 (Substitute) U.S. Department of Commerce Application Number Filing Date June 28, 2006 Patent and Trademark Office First Named Inventor Jacob Bar-Tana Art Unit INFORMATION DISCLOSURE STATEMENT Examiner Name M. Sznaidman (Use several sheets if necessary) 2224/76581/JPW Attorney Docket No. /ACK U.S. PATENT DOCUMENTS Examiner Cite Document Number Publication Date Name of Patentee or Applicant of Cited Document Number-Kind Code2 (if known) Initials\* No.1 MM-DD-YYYY 2 4,634,795 01-06-1987 Bar-Tana 3 4.711.896 12-08-1987 Bar-Tana et al FOREIGN PATENT DOCUMENTS Examiner Cite Foreign Patent Document Publication Date Name of Patentee or T6 Initials\* No. | Country Code3 Number4 Kind Code5 (if know MM-DD-YYYY Applicant of Cited Document

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 60Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds of Codes of USPTO Patent Documents a<u>tyww.uspto.gov</u> or MPEP 901.04. 3 Enter Office that issuedthe document, by the twoletter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of threat document, 'Kind of document by the appropriate symbols as indated on the document under WIPO Standard ST.16 if possible Applicant is to place a check mark here if English Language Translation is attached.

DATE CONSIDERED

/Marcos Sznaidman/

EVAMINED

SIGNATURE

Applicants: Jacob Bar-Tana and Ihor Bekersky Serial No.: 10/585,017

10/24/2011

## Form PTO-1449 (Substitute) U.S. Department of Commerce Patent and Trademark Office

Application Number	10/585,017
Filing Date	June 28, 2006
First Named Inventor	Jacob Bar-Tana
Art Unit	1612
Examiner Name	M. Sznaidman
Attorney Docket No.	2224/76581/JPW

## INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

		Attorney Docket No. /ACK	v=
		NON PATENT LITERATURE DOCUMENTS	
	Cite No.1	Include name of the author (n CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volumeissue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		October 4, 2010 Supplementary European Search Report issued in connection with European Application No. EP 04 80 6716	
		PCT International Application Publication No. WO 99/00116 A2, published January 7, 1999 (Bar-Tana)	
	5	Russell et al., "Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by $\beta, \beta'$ -tetramethylhexadecanedioic acid (MEDICA 16), Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15., no. 7, 1995	
	6	McCarty, M.F., "Peroxisome proliferators as adjuvants for the reverse-electron-transport therapy of obesity: An explanation for the large increase in metabolic rate of MEDICA 16-treated rats," Medical Hypotheses, vol. 53, no. 4, 1999	
EXAMINER SIGNATURE		/Marcos Sznaidman/ DATE CONSIDERED 10/24/2011	

EXCHATURE //MallOS SZRIGITIMI/ DATE CONSIDERED 10/24/2011

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not-sinformance and not considered. Include copy offits from with next communication to applicant/Applicant's unique citation designation number (optional)Applicant is to place a checkwark here if linglish language Trenslation is stated.